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)* 	xenograft, whole exome next generation sequencing, copy number aberration, 
transcriptome, phosphotyrosineproteomics, mass spectrometry, DNA methylation, nonsmall 
cell lung cancer 
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			
Nonsmall cell lung cancer is characterized by heterogeneous histology and genetics profile, 
driving the need for translational models that are clinically relevant. Many models would be 
required to represent the potential diverse mechanisms of lung cancer pathogenesis. 
Our PDX resource currently has the largest number of lung cancer models representing the major 
histological subtypes. Comprehensive genomic proteomic profiles showed fidelity to the 
molecular pathology of their original human tumors in a subset of these models. 
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Availability of lung cancer models that closely mimic human tumors remains a significant gap in 
cancer research, as tumor cell lines and mouse models may not recapitulate the spectrum of lung 
cancer heterogeneity seen in patients.  We aimed to establish a patientderived tumor xenograft 
(PDX) resource from surgically resected nonsmall cell lung cancer (NSCLC). Fresh tumor 
tissue from surgical resection was implanted and grown in the subcutaneous pocket of nonobese 
severe combined immune deficient (NOD SCID) gamma mice. Subsequent passages were in 
NOD SCID mice. A subset of matched patient and PDX tumors and nonneoplastic lung tissues 
were profiled by whole exome sequencing, single nucleotide polymorphism (SNP) and 
methylation arrays, and phosphotyrosine (pY)proteome by mass spectrometry. The data were 
compared to published NSCLC datasets of NSCLC primary and cell lines. 127 stable PDXs were 
established from 441 lung carcinomas representing all major histological subtypes: 52 
adenocarcinomas, 62 squamous cell carcinomas, 1 adenosquamous carcinoma, 5 sarcomatoid 
carcinomas, 5 large cell neuroendocrine carcinomas, and 2 small cell lung cancers. Somatic 
mutations, gene copy number and expression profiles, and pYproteome landscape of 36 PDXs 
showed greater similarity with patient tumors than with established cell lines. Novel somatic 
mutations on cancer associated genes were identified but only in PDXs, likely due to selective 
clonal growth in the PDXs that allows detection of these low allelic frequency mutations.  The 
results provide the strongest evidence yet that PDXs established from lung cancers closely mimic 
the characteristics of patient primary tumors.  
	
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Lung cancers are grouped broadly into small cell lung cancer (SCLC, 15%) and non
small cell lung cancer (NSCLC, 85%). Except for very early stage tumors, they collectively lack 
curative treatments and account for the greatest number of cancerrelated deaths worldwide 
1
. 
Recent comprehensive genomic profiling of primary patient tumors belonging to the two most 
common NSCLC histological classes 
2, 3
, adenocarcinomas (AdC) and squamous cell carcinoma 
(SqCC) has provided new insights into the molecular complexity of these malignancies.  Patient 
tumors are very heterogeneous histologically and genomically, with common cancer driver 
mutations mostly being restricted to <10% of patients, except for 	
 and  
4
.  This 
finding suggests that a large number of independent tumor models will be necessary to model the 
potential diverse mechanisms of lung cancer pathogenesis accurately.  
Over decades, multiple tumor models have become available for the study of NSCLC, 
including cell lines established from patient tumors 
57
, genetically engineered mouse models 
(GEMMs) 
8, 9
, and patientderived tumor xenografts (PDXs) 
10, 11
 . However, it remains unclear 
how well these preclinical tumor models recapitulate patient tumor biology. Some reports 
suggest that when the molecular profiles of patient tumors are compared to established cell lines, 
there is substantial genetic divergence between primary lung cancers and cell lines 
1214
. This 
observation raises the concern that cellular and biochemical mechanisms unique to culture
adapted cell lines growing on 2dimensional conditions may not adequately reflect the full 
spectrum of key processes in patient tumors, and hence, may not accurately model patient 
responsiveness to cancer therapies 
1517
. This may contribute to and explain the high failure rates 
of early phase trials in cancer drug development 
18
, as most preclinical drug studies are 
conducted using established cell lines.  Spontaneously formed tumors in GEMMs driven by 
single or limited number of genes also may be limited in addressing therapeutic responses 
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relevant to patient tumors 
19, 20
, as they lack the substantial complexity of genomic alterations 
associated with patient tumors. Thus, PDX models ultimately may be better preclinical tumor 
models for oncology drug studies, as they may better mimic the genetic heterogeneity and 
biological complexity of clinical cancers 
21, 22
.   
We and others have reported the establishment of transplantable NSCLC tumors directly 
from patients to immunedeficient mice. These PDXs bear close histopathological resemblance 
to their corresponding primary cancers and they recapitulate patient responses to a number of 
therapeutic agents 
10, 19, 23, 24
.  However, it is still unclear to what extent they fully recapitulate the 
genetic, epigenetic, and signaling mechanisms that collectively drive clinical disease, especially 
for their matched patient tumors. At a broad level, PDXs harbor similar NSCLC profiles of gene 
copy number 
25
, mRNA
10
 and protein,
26
  and retain specific “driver” mutations of the matching 
primary tumors 
10, 11, 2527
. Here, we now report the high concordance of genomewide exomic 
single nucleotide variants (SNVs) and gene copy number variants (CNVs) between 25 PDXs and 
their matched patient tumors, which comprehensively establishes the ability of PDXs to 
faithfully recapitulate the genetic mechanisms driving pathobiology of their specific 
corresponding patient tumors.  Furthermore, from a total of 36 PDXs, we use SNV, CNV and 
gene expression, as well as previously unexamined DNA methylation and phosphotyrosine (pY) 
proteome profiles to compare similarities between PDXs and publically described NSCLC 
primary tumors and established cell lines.  
 
 
		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The protocol for collection of tumor samples from surgically resected earlystage NSCLC 
to establish PDXs was approved by The University Health Network Human Research Ethics and 
Animal Care Committees. Patient tumor samples were obtained by informed consent. Tumor 
specimens were divided into small pieces (2 mm), mixed with 10% Matrigel at 4°C (Becton 
Dickinson Biosciences, San Jose, CA), and implanted into the subcutaneous flank tissue of non
obese diabetic severe combined immune deficiency (NOD SCID) gamma mice. All mice were 
bred in our facility, housed under sterile conditions, and given autoclaved food and water ad 
libitum. Once tumors reached 11.5 cm in diameter, as measured with calipers, mice were 
euthanized and tumors were implanted/passaged serially into new NOD SCID mice for at least 
three times to establish model stability. Harvested tumors were divided equally for 
cryopreservation, quick freeze in liquid nitrogen and preparation of formalinfixed paraffin
embedded tissue blocks. Comprehensive profiling on PDXs was conducted from early passages 
24.  
 
	%	*
				#-	
Genomic DNA samples were isolated from 36 PDX tumors, 25 available matched snap
frozen banked primary tumors and 29 matched normal lung tissues. The whole exome was 
captured using a SureSelect Human 50Mbp kit (Agilent Technologies, Santa Clara, CA) 
according to the manufacturer's instructions. For targeted resequencing, we prioritized regions 
with somatic SNVs found by exome sequencing of both PDX and patient tumors and captured 
those regions using a SureSelect Custom 2Mbp kit. Captured DNA was sequenced using the 
HiSeq platform (Illumnina, San Diego, CA) and pairedend sequence reads were generated for 
each sample. Xenome 
28
 was used to first identify and remove contaminating reads from the 
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mouse stroma for PDX samples. Basic alignment and sequence quality control was done using 
Novoalign v3 and Picard v1.78. Mapped exomes were processed by the standard Genome 
Analysis Toolkit (GATK) for quality control, variant calling, and mutational significance 
analysis. Somatic mutation calling with matched normal samples was also performed using 
Strelka v1.0 
29
. Mutations called by both GATK and Strelka were included in the targeted 
capture. High confidence variants in PDXs included only mutations called by both exome and 
targeted sequence analysis, or called in only exome sequence analysis but also found in the 
Catalogue of Somatic mutations in Cancer (COSMIC) database v70.     
 
!	(	&		
Genomic copy number was measured using the HumanOmni 2.5 BeadChip single 
nucleotide polymorphism (SNP) array platform (Illumina). The total signal intensity (LogR) and 
Ballele frequency (BAF) values were reported at each genomic locus that was profiled by the 
SNP array. The relative copy number gains or losses of genomic regions were identified using 
the allelespecific copy number analysis of tumors (ASCAT) segmentation algorithm 
30
. Each 
gene was mapped to a genomic region if more than 50% of the gene overlapped with the region. 
We reported the average log likelihood ratio (LRR) for each gene, which quantifies the copy 
number gain in the tumor relative to normal tissue. For instance, a LRR=0.5 was considered copy 
number gain, and LRR=0.5 was considered copy number loss. The gene copy number data from 
the 36 PDXs have been deposited in the Gene Expression Omnibus with GSE68929 
	
				
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RNA from 36 PDX samples was labeled and amplified using the whole genome gene 
expression DASL HT Assay (Illumina) for partially degraded, FFPE derived RNA. The labelled 
samples were hybridized onto Human HT12 V4 BeadChips and processed as per the 
manufacturer’s protocol, and scanned on the iScan (Illumina). The data files were quantified in 
GenomeStudio Version 2011.1. All the samples passed Illumina sample dependent and 
independent QC Metrics.  Raw intensity data was log2 transformed and quantile normalized by 
the lumi R package 2.11.1.  Batch effects from microarray assays conducted on different dates 
were adjusted using ComBat (sva R package) with default settings. A list of differentially 
expressed genes between SqCC and AdC PDXs was identified by analysis of variance 
(ANOVA) at adjusted P<0.01. We used Gene Set Enrichment Analysis (GSEA) to test whether 
the 131 upregulated genes in AdC and 289 genes upregulated in SqCC PDXs were also 
differentially expressed in patient tumors from the JBR.10 study, GSE14814 
31
. 
The gene expression data from the 36 PDXs and corresponding patient tumors have been 
deposited in the Gene Expression Omnibus with GSE68929. 
	
%&	
	!
	
The bisulfiteconverted DNA samples of tumors and matched patient normal samples 
were hybridized to the Illumina Infinitium HumanMethylation450 BeadChip and processed as 
per the manufacturer’s protocol. The values M and Beta were background corrected and quantile 
normalized using the lumi R package 2.11.1. The log ratio between M values between tumor and 
normal samples defined the somatic methylation score.  The methylation score for each gene was 
an average over all probes +1500bp and 500bp of the transcription start site.  
$

	./0	$		
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Total protein was extracted in urea lysis buffer, reduced and alkylated, and subjected to 
overnight tryptic digestion as described previously 
26
. Peptides were purified by passing through 
a C18 column, eluted with 50% acetonitrile and vacuum dried. The pY peptides were enriched 
using a PTMScan® Phosphotyrosine Mouse mAb (PTyr100) kit as instructed by the 
manufacturer’s protocol (Cell Signaling Technology, Danvers, MA).  The enriched pY peptides 
were separated on an EasySpray column using an instrument with a combination of liquid 
chromatography and mass spectrometry systems (LCMS/MS, Thermo Scientific, Odense 
Denmark) 
32
. Acquired raw files were analyzed and quantified using MaxQuant software 
(version 1.3.0.5) 
33
. The Andromeda probabilistic search engine 
34
 was used to search peak lists 
against the SwissProt database (2013 version), with default search parameters as previously 
described 
35
. The proteomics data described in this paper have been deposited to the 
ProteomeXchange Consortium (http://www.proteomexchange.org) via the PRIDE partner 
repository with the dataset identifier PXD000809. A detailed method is described in 
Supplementary Method S1.   
	
$(	%	
The Cancer Genome Atlas (TCGA) has the most extensive catalogues of mutations, gene 
copy changes, DNA methylation and gene expression data for the lung cancer subtypes AdC 
3, 36
 
and SqCC 
2
; data for 401 patients were downloaded from cBioportal (July 2014 version). Copy 
number gains and losses were determined using a LRR cutoff of ±0.5. RNA expression data 
derived from RNAseq by ExpectationMaximization (RSEM) format. The transcriptome of 
NSCLC was downloaded from GSE14814 dataset 
31
 . The phosphoproteome for NSCLC of 150 
patients and 41 cell lines were acquired from Rikova et al. 
37
. Broad CCLE cell line mutation, 
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copy number and expression data were downloaded from the October 2012 version of their data 
portal (http://www.broadinstitute.org/ccle/data/). 
 
				
*	
All somatic mutations and their flanking bases were compiled and compared to pre
defined signatures from COSMIC (http://cancer.sanger.ac.uk/cosmic/signatures). We determined 
the linear combination of predefined signatures that most accurately reconstructed the 
mutational profile of a single tumor sample. A multiple linear regression model was used with 
the caveat that any coefficient must be greater than 0, as negative contributions are not possible 
in a biological sense.  
Gene sets corresponding to pathways found in KEGG and Reactome databases were 
extracted. Mutations (somatic, wildtype) and copy number alterations (gain, loss, diploid) for 
each pathway were used as input features for iClusterPlus 
38
. The model that maximized 
Bayesian information criterion was selected for each pathway and the proportion of variation 
explained was reported. To identify the expression pattern associated with each pathway 
alteration profile, we used the Random Forests algorithm (R package random Forest) running 
1000 trees on all gene expression profiles and identified the top 100 expression profiles 
according to their importance scores. 
	
	
$						(	$%,		
A total of 441 resected primary lung carcinomas were implanted into NOD SCID mice 
and 127 (29%) patientderived tumor xenografts (PDX) generated stable growth, which could be 
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passaged serially (Fig. 1A). Among 264 NSCLC patients with at least 3years followup, patients 
whose tumors formed stable PDXs ( those who did not) showed significantly worse 
diseasefree survival (DFS, HR=3.12, 95% CI =2.024.83, P<0.0001) and overall survival (OS, 
HR=4.08, 95% CI =2.167.73, P<0.0001), even after adjusting for sex, stage and differentiation 
(Fig. 1BC). Close histological similarities were observed between PDXs and their 
corresponding patient tumors (Fig. 1DK), as shown in four paired tumors representing 
adenocarcinoma (AdC, DE), squamous cell carcinoma (SqCC, FG), sarcomatoid carcinoma 
(SC, HI) and largecell neuroendocrine carcinoma (LCNEC, JK). Thirty six (15 AdC, 18 
SqCC, two LCNEC and 1 SC) PDX models were comprehensively profiled by fiveomics 
methods: exome, gene copy number, DNA methylation, mRNA expression, and pY proteome, 
and the matched patient tumor and adjacent normal tissue for a subset of PDXs were also 
analyzed by some of the platforms (Table 1 and Supplementary Tables S1 and S2).  
 
			#!!	$%,		
				
Given the large number of heterogeneous mutations in NSCLC across patients, PDXs can 
be a powerful resource to study diverse genetic mechanisms of pathogenesis, provided they 
faithfully retain the mutation spectrum of the specific patient tumors from which they are 
derived.  To investigate this possibility, we conducted whole exome sequencing of 36 PDXs, and 
their corresponding 25 patient tumors and 29 normal adjacent tissues, with few patients having 
insufficient specimen or poor specimen quality for analyses.  The exome sequence of PDX tumor 
cells was additionally enriched over stromal sequence by removing any sequence reads that 
aligned better to the mouse rather than human genome. Approximately 8899% of SNVs found 
in the primary tumor were retained in the matched PDX tumor (1093373 SNVs/model) 
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(Supplementary Fig. S1). Of common SNVs, 70% (7,507) were detected at <50% variant allele 
frequency (VAF) in both paired PDXpatient tumors, and 16% (1,763) had >50% VAF in PDXs, 
but <50% VAF in primary tumors (Supplementary Fig. S2). In contrast, only 6% of common 
SNVs (664) had VAFs greater in primary tumors than in PDXs. This enrichment of VAF in 
PDXs was significant (Chisquared test P<2.2 x10
6
)1	We performed	targeted resequencing of 31 
PDX tumors at loci where somatic SNVs were found by exome sequencing and verified 6,419 
unique nonsynonymous SNVs, for a 59.4% verification rate (Supplementary Fig. S3).  
PDXs also recapitulated genomewide CNVs that are characteristic of their matched 
patient tumors (Fig. 2A, B). For example, between PDXs and patient tumors, common copy 
number gains were observed on chromosome 7 and 5p of AdCs, while focal amplifications of 

 and were shared in several SqCCs. We also observed that the signal intensity from 
copy number profiling on PDXs was higher than from matched patient tumors. This led to a 
higher resolution view of CNVs and histologyspecific copy number gains and losses, using the 
PDXs as compared to patient tumors. A greater signal for copy number estimates were obtained 
from PDXs as compared to their matched primary tumors, as represented in the models 148 AdC 
and 77 SqCC (Supplementary Fig. S4).  In addition, we observed an increased signal for loss of 
heterozygosity from the B allele frequencies at loci with known copy alterations. 
We also compared the spectrum of genetic alterations in our patient tumors and 
corresponding PDXs to that observed in NSCLC TCGA patient and Cancer Cell Line 
Encyclopedia (CCLE) data. Of these validated nonsynonymous SNVs, only 27% (1,728) have 
been reported in the Catalogue of Somatic Mutations in Cancer (COSMIC). The amount of 
mutation burden in each PDX was comparable to that in primary lung tumors from The Cancer 
Genome Atlas (TCGA) (Supplementary Table S3), and was lower than reported in the 70 
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NSCLC CCLE cell lines 
39
. 	In addition to known mutations, we found several nonsynonymous 
somatic mutations in oncogenes and tumor suppressor genes that have not been reported to date 
in the COSMIC 
40
 (Supplementary Table S4).  
We found that many broad and focal copy amplifications and deletions were shared 
(Supplementary Fig. S5). Notably, PDX AdC copy number variants (CNVs) were more similar 
to patient tumors (=0.69) than to AdC cell lines (0.35) based on the logR ratio of CNVs. 
Overall, the number of genes somatically altered (mutation and CNV) in the PDXs was most 
similar to patient tumors and was lower than in cell lines (Supplementary Fig. S6). These data 
support our PDXs being appropriate models to study the same type of genetic diversity observed 
in a larger cohort of NSCLC patients. 
 
 

	

	./0		$%,							
			
		
Alterations in phosphotyrosine (pY) signaling occur widely in cancer, including NSCLC, 
and contribute to a number of oncogenic mechanisms 
37, 41
.  Although PDXs recapitulate the 
genetic alterations associated with primary patient tumors, it has not yet been reported whether 
they also retain global PTyr patterns.  Due to limitations on patient material, we focused on 
using a liquid chromatographymass spectrometry (LCMS) method to detect pY sites on 351 
proteins in 31 PDXs, and then compared these pY profiles to published pY datasets of NSCLC 
cell lines, patient tumors, and corresponding normal lung tissues 
37
.	Hierarchical and principal 
components clustering across tyrosine kinases and other subsets of genes in the pYproteome 
showed greater similarity between patient and PDX tumors than to cell lines (Fig. 3A).  
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Furthermore, the PDXs and patient tumors tended to have more variable and lower levels of 
tyrosine phosphorylation than cell lines (Fig. 3 B, C), suggesting cell lines may have an overall 
greater dependency on high levels of phosphotyrosine signaling by specific kinases. 
 
		
		
2	
	(		#!!	
Having established the fidelity of PDXs to recapitulate the genetic characteristics and P
Tyr signaling patterns of patient tumors, we then performed hierarchical clustering of the 200 
most variable DNA methylation sites at gene promoters across 36 PDXs differentiated the 
tumors according to their histological subtypes (Fig. 4A). Similar to methylation, hierarchical 
clustering based on a profile of the 200 most variably expressed genes separated the PDXs 
according to their paired patient tumor histological subtypes (Fig. 4B). The PDX DNA 
methylation or gene expression patterns that correlated with histological subtypes also predicted 
correctly the subtypes of independent NSCLC patient tumors. Based on the identification of 
hyper and hypo methylated regions along the genome by probing genes and cytosine
phosphateguanine (CpG) islands, a principal component clustering analysis showed that the 
methylation profiles of PDXs were more variable than patient tumors from the TCGA dataset 
(Fig. 4C); however, PDX and patient tumors of the same histological subtype clustered closely. 
Using 131 genes that were differentially upregulated in AdC PDXs and 289 genes upregulated 
in SqCC PDXs  (absolute fold change >2, P<0.001) and applying them to 133 stage I and II 
NSCLC patient samples (GSE GSE14814), these sets of genes also were upregulated and 
enriched in the same subtypes of patient tumors (Fig. 4D, p<0.001). 
	
&		3					
*	
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Known oncogenic mutations identified in PDXs included  in 31 (86%), 	
 in 9 
(25%), in 2 (6%) and 	 in 2 (6%) models (Fig. 5A). The cooccurrence of multiple 
somatic mutations and copy number aberrations were detected among the PDXs models. Gene 
sets were identified and associated with specific pathways that contained these alterations. 
Integrative clustering using iClusterPlus then was applied to the PDX genomic profiles to 
estimate the proportion of variation explained by alterations in each pathway (Supplementary 
Fig. S7A). Genes regulating cell cycle, including , were altered in all PDX models except 
one (X207), and integrative clusters based on those alterations explained ~50% of the variation 
in the PDX genomic landscape (Fig. 5B). The occurrence of alterations in specific gene sets, 
such as AKT signaling, MAPK signaling and metabolic pathways was correlated with activity in 
cell signaling processes manifested in both the phosphoproteomic (Supplementary Fig. S7B) 
and mRNA levels (Fig. 5C). Genomic alterations in the CTLA4 signaling pathway were frequent 
across PDXs and cooccurred with alterations in cell cycle and AKT signaling pathways. For a 
subset of these PDXs, we also observed enrichment of genes related to the positive regulation of 
the immune system.  
 
	
%	
In this study, we have confirmed with twice the number of patients and longer followup 
our previous finding that the ability of NSCLC to grow as a xenograft in mice is a strong poor 
prognostic indication for patient survival 
11
. Furthermore, we have utilized five comprehensive 
omics platforms including exome, gene copy number, DNA methylation, mRNA expression and 
pYproteome, to characterize 36 of the PDX models. The separation of histological subtypes 
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AdC and SqCC was observed consistently at all levels of the omics profiles. The comparison of 
the PDX derived data to matched patient tumors, other cohorts of lung cancer patient tumors 
2, 3, 
36
 and established cell lines 
37, 39
 showed that across gene mutations, copy number alterations and 
phosphoproteins, there were greater similarities between PDXs to patient tumors than to cell 
lines. This fidelity and diversity illustrates an advantage of PDX models as preclinical model 
over cell lines or other tumor models, including xenografts formed from established cell 
lines and genetically engineered mouse models (GEMMs). While GEMMs have an advantage in 
studying the biology of a single or combination of two genetic abnormalities, their utility is 
limited to the available models that represent few specific genetic abnormalities and histological 
types of lung cancers 
42, 43
.         
The high recapitulation of the genomic landscape across NSCLC histological subtypes 
when PDXs were compared to lung primary tumors 
2, 3, 36
 as shown in this study, is consistent 
with omics studies comparing PDXs of breast and colon cancers to their corresponding patient 
tumors 
44, 45
. This contrasts to cell lines, which in previous comparisons to patient tumors have 
shown low correlation between their point mutation frequencies ( ), and marked 
differences in their mRNA and copy number profiles 
15, 39
. Recently, Gao  
22
 reported similar 
results of closer similarities for mutation rates and copy number landscape between PDXs 
models established across common adult solid cancers, including 42 NSCLC models, and data 
from primary patient tumors (TCGA) and cell lines (CCLE).   
By measuring the variant allele frequency, we have shown that a significant proportion of 
SNVs were detected at higher frequencies in PDXs compared to their corresponding primary 
tumors. This could be due to higher tumor cellularity in PDXs compared to primary patient 
tumors, which often have greater stromal and inflammatory cell infiltrates, which are lost during 
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engraftment in immunedeficient mice 
46
. Higher VAFs could also result from selective 
enrichment of clones harboring mutations that favor higher growth rates and/or more aggressive 
cancer biology 
47
. Genomic alterations in cell cycle pathways were the most frequently found 
changes in PDXs.  
While the ability of these PDXs to model histology and the omic profiles is an advantage 
for their utility as preclinical models, their murine host may hinder specific experimental 
conditions. Our observation that lower levels of cMET phosphorylation occurring in PDXs 
compared to cell lines may be a consequence of the inability of the murine hepatocyte growth 
factor to activate human cMET tyrosine function 
48
. The NOD SCID strain also lacks an 
immune system which would prevent the testing of therapeutic strategies that require activation 
of immune response. Possible alternate murine hosts could include nude or SCID strains which 
have a greater representation of the immune components, or a humanized mouse host by 
reconstitution of human hematopoietic stem cells 
49
.  Nevertheless, we observed a subgroup of 
PDX tumors with genomic alterations in CTLA4 pathways modulating immune checkpoints that 
resulted in upregulation of immune system genes 
50
. 
Preclinical models, including PDXs derived directly from patient tumors are emerging as 
the preferred platform for translational lung cancer research 
39, 44
. Some evidence, including 
studies from our lab, shows that NSCLC PDX models respond similarly to pharmacological 
agents when compared to their matched patient tumors 
19, 24
, indicating that high throughput 
screening strategy using large number of PDX models may be used preclinically to assess 
population responses to novel therapeutics 
22
. Genomicscharacterized PDXs models may also 
enable systematic investigation on the underlying biology and mechanisms of drug response or 
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treatment resistance, identify potential predictive biomarkers for novel drugs, and contribute to 
the design of early phase clinical trials. 
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(	;1	%
				*

	$%,		1	
	
 
$	
.A>?0 
&		 Median(range)  65.2(44.179.9) 
#		 F  14 (38.9%) 
	 M  22 (61.1%) 
'		 AdC 15 (41.7%) 
	 SqCC 18 (50.0%) 
	 Sarcomatoid  1 (2.8%) 
	 LCNEC  2 (5.5%) 
		 WD  1 (2.8%) 
	 MD  15 (41.7%) 
	 PD  20 (55.5%) 
#3	 No 4 (11.1%) 
	 Yes 32 (88.9%) 
#		 I 19 (52.8%) 
	 II 5 (13.9%) 
	 III 8 (22.2%) 
	 IV 4 (11.1%) 
			 T1  4 (11.4%) 
	 T2  26 (72.2%) 
	 T34  6 (17.1%) 
			 N0  24 (66.7%) 
	 N13  12 (33.3%) 
			 M0  32 (88.9%) 
	 M1  4 (11.4%) 
	2		 Median(range)  4.5 (2.111) 
&B	
		
N  32 (88.9%) 
Y  4 (11.1%) 
&B	!
1		
N  21 (58.3%) 
Y  15 (41.7%) 
			 CIF at 3 years  38% 
#		 KM  at 3 years  53% 
C*5		 Median(range) 5.3 (0.27.3) 
WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; CIF, 
cumulative incidence function; KM, KaplanMeier. 
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C		
	
C	;1	(
		$%,			#!!		1 (A) A flow diagram 
describes the steps taken to establish a stable PDX line. (B) KaplanMeier survival curves of 
stable PDX (XG) and noPDX (noXG) patients show a significant difference in diseasefree 
survival. (C) Multivariate analysis shows xenograft engraftment as a prognostic feature. 
Representative histology of the four NSCLC subtypes show paired patientPDX tumors: 
adenocarcinoma (D/E, model 82, Apatient/Bxeno), squamous cell carcinoma (F/G, model 57), 
sarcomatoid (H/I, model 134) and large cell neuroendocrine carcinoma (J/K, model 88). Slides 
were stained with hematoxylin and eosin and images were captured on an Aperio ScanScope XT 
(Leica Biosystems). 
 
C	<1	#				#!!	$%,			
		
1 (A) Copy number alteration frequencies across the genome for PDXs and 
corresponding patient tumors. A more stringent threshold for copy gain and loss was applied to 
PDX copy number profiles compared to that of patient tumor. Gene alterations characteristic of 
adenocarcinoma (AdC) and squamous cell carcinoma (SqCC) are labelled. 
	
C	>1 !	

			#!!	$%,5					
1	The activated tyrosine phosphorylation in 365 proteins in our PDXs was compared to 
publicly available NSCLC datasets of normal, patient, and cell line samples reported by Rikova, 
5 
37
. (A) Samples along columns are sorted by hierarchical clustering across phosphorylated 
proteins. Bar plots underneath heatmaps show the relative proportions of proteins with a spectral 
count >5. (B) Tyrosine kinase phosphorylation profiles in our PDX are compared to normal, 
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patient, and cell line samples from Rikova, . Samples are grouped by hierarchical clustering 
(dendogram), and the first two principal components (scatterplot).  (C) A heatmap comparing 
phosphorylation status of receptor tyrosine kinase proteins and phosphatases. Phosphorylated 
proteins in yellow have a spectral count ≥ 1. Samples are ordered by hierarchical clustering 
showing PDXs (green), cell lines (pink) and patient tumor (blue). 
	
C	71	$%,					
					
1 Heat maps show hierarchical clustering of (A) the 200 most variable DNA methylation 
sites at promoter regions, or (B) the 200 most variable mRNA expressions of xenograft tumors 
corresponds to the histology subtypes of matched patient tumors. (C) The principal component 
clustering of DNA methylation profiles in TCGA patient tumors and PDXs is separated by 
histological subtypes. (D) Gene set enrichment analysis was performed on genes highly 
expressed in either AdC or SqCC of PDXs and compared to patient AdC or SqCC of GSE14814 
dataset in a hypergeometric distribution. 
 
C	:1	)		(						
*1 (A) Verified 
mutations in key cancer associated genes across PDX tumors. The percentage of lung xenograft 
models is shown by the bar graph. Samples are listed according to histology classification. 
Somatically mutated genes listed vertically are grouped as AdC (red), SqCC (blue), Other 
(green) based on their prevalence in human patient tumors. Within each group, the genes are 
listed in decreasing order of nonsilent somatic mutation prevalence in xenografts. Colored 
rectangles indicate mutation category in a given gene and tumor. White boxes indicate unknown 
status or silent mutations. (B) Genomic alterations (somatic mutation or copy number loss/gain) 
across 36 PDXs in cancer associated pathways that explained a > 20% genomic variation 
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according to iClusterPlus. (C) Expression signature of 100 genes selected by RandomForest as 
correlated with the pattern of the DNA alterations in panel (B). High expression (> 2 zscore) are 
colored red and low expression (< 2 zscore) are colored blue. 
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3. Comparative phosphotyrosine profiles of NSCLC PDXs, cell lines and primary tumors. The activated 
tyrosine phosphorylation in 365 proteins in our PDXs was compared to publicly available NSCLC datasets of 
normal, patient, and cell line samples reported by Rikova, et al. 37. (A) Samples along columns are sorted 
by hierarchical clustering across phosphorylated proteins. Bar plots underneath heatmaps show the relative 
proportions of proteins with a spectral count >5. (B) Tyrosine kinase phosphorylation profiles in our PDX are 
compared to normal, patient, and cell line samples from Rikova, et al. Samples are grouped by hierarchical 
clustering (dendogram), and the first two principal components (scatterplot).  (C) A heatmap comparing 
phosphorylation status of receptor tyrosine kinase proteins and phosphatases. Phosphorylated proteins in 
yellow have a spectral count ≥ 1. Samples are ordered by hierarchical clustering showing PDXs (green), cell 
lines (pink) and patient tumor (blue).  
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